Federated Hermes Inc. Lowers Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Federated Hermes Inc. cut its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 57.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 823,487 shares of the company's stock after selling 1,123,613 shares during the quarter. Federated Hermes Inc. owned 1.71% of Amphastar Pharmaceuticals worth $30,576,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Pacer Advisors Inc. grew its position in Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after acquiring an additional 1,347,775 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Amphastar Pharmaceuticals in the third quarter worth approximately $957,000. XTX Topco Ltd purchased a new position in shares of Amphastar Pharmaceuticals in the third quarter worth $674,000. Geode Capital Management LLC raised its holdings in Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock valued at $44,674,000 after buying an additional 14,015 shares during the last quarter. Finally, D.A. Davidson & CO. purchased a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at $417,000. 65.09% of the stock is currently owned by institutional investors.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 27.10% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

AMPH has been the topic of a number of analyst reports. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st.

Amphastar Pharmaceuticals Stock Up 1.5 %

Shares of AMPH stock traded up $0.36 during midday trading on Monday, reaching $24.52. 75,317 shares of the stock were exchanged, compared to its average volume of 455,670. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.74 and a 1 year high of $53.96. The firm has a market cap of $1.17 billion, a PE ratio of 8.17, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The company's 50 day moving average is $28.68 and its two-hundred day moving average is $38.07. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.